At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Verinurad +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, 3-Period, Cross-Over Phase I Study to Investigate the Effect on the QTcF Interval of a Single Dose of 2 Different Doses of Verinurad, Each in Combination With Allopurinol 300 mg, Compared With Placebo In Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Verinurad, Placebo, and 1 other intervention for Healthy Volunteers (Intended Indication: Chronic Kidney Disease). Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval
Study Details
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMar 2020
Primary CompletionAug 2020
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartMar 3, 2020
Primary CompletionAug 21, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago
Interventions
Verinuraddrug
Randomized subjects will receive oral dose of verinurad
Placebodrug
Randomized subjects will receive oral dose of placebo
Allopurinoldrug
Randomized subjects will receive oral dose of allpurinol (Treatment A and B)